The Institute of Medicine has released the summary of a workshop it hosted last July to discuss the economic issues likely to arise in the age of genomic medicine.

The workshop brought together economists, regulators, payors, researchers, patients, and other stakeholders to discuss various economic factors likely to influence the integration of genomic data into healthcare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.